DK200601181A - Fiskevaccine - Google Patents
Fiskevaccine Download PDFInfo
- Publication number
- DK200601181A DK200601181A DK200601181A DKPA200601181A DK200601181A DK 200601181 A DK200601181 A DK 200601181A DK 200601181 A DK200601181 A DK 200601181A DK PA200601181 A DKPA200601181 A DK PA200601181A DK 200601181 A DK200601181 A DK 200601181A
- Authority
- DK
- Denmark
- Prior art keywords
- protein
- polypeptide
- carrier
- seq
- nucleic acid
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 2
- 241000251468 Actinopterygii Species 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 101710125507 Integrase/recombinase Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 241000972773 Aulopiformes Species 0.000 claims 2
- 235000019515 salmon Nutrition 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (10)
1. Polypeptid omfattende en aminosyresekvens med mindst 90% aminosyre-identitet i forhold til en vilkårlig af SEQ ID NO: 1-3 i en region svarende til nævn* te SEQ ID NO, kendetegnet ved, at polypeptidet er mindst 95 og højst 166 aminosyrer i størrelse.
2. Protein omfattende et polypeptid ifølge krav 1, hvor nævnte protein ikke omfatter en del af et lakse-a-virus (SAV) E2-protein omfattende nævnte polypeptid og større end 166 aminosyrer i størrelse.
3. Polypeptid omfattende en del af et SAV E2-protein, kendetegnet ved, at nævnte del har mindst aminosyresekvensen fra SEQ ID NO: 4 og højst amino-syresekvensen fra SEQ ID NO: 6.
4. Protein omfattende et polypeptid ifølge krav 3, hvor nævnte protein ikke omfatter en del af SAV E2-proteinet omfattende nævnte polypeptid og værende større end nævnte polypeptid.
5. Bærer omfattende et protein ifølge et vilkårligt af kravene 2 eller 4.
6. Fremgangsmåde til at producere lakse-a-vims-neutraliserende antistoffer omfattende trinnene: a) podning af et polypeptid ifølge et vilkårligt af kravene 1 til 3, et protein ifølge et vilkårligt af kravene 2 eller 4 eller en bærer ifølge krav 5 i et dyr og b) isolering af antistoffer.
7. Nukleinsyre, der koder for et polypeptid ifølge et vilkårligt af kravene 1 eller 3, eller et protein ifølge et vilkårligt af kravene 2 eller 4.
8. Bærer omfattende en nukleinsyre ifølge krav 7, hvor nævnte bærer er valgt fra gruppen bestående af et DNA-fragment, et rekombinant DNA-molekyle, en levende rekombinant bærer og en værtscelle.
9. Vaccine omfattende et polypeptid ifølge et vilkårligt af kravene 1 eller 3, et protein ifølge et vilkårligt af kravene 2 eller 4, en bærer ifølge et vilkårligt af kravene 5 eller 8, eller en nukleinsyre ifølge krav 7 og en farmaceutisk acceptabel bærer.
10. Diagnosekit omfattende et polypeptid ifølge et vilkårligt af kravene 1 eller 3, et protein ifølge et vilkårligt af kravene 2 eller 4, en bærer ifølge et vilkårligt af kravene 5 eller 8 eller en nukleinsyre ifølge krav 7.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05020223 | 2005-09-16 | ||
| EP05020223 | 2005-09-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK200601181A true DK200601181A (da) | 2007-03-17 |
| DK179025B1 DK179025B1 (da) | 2017-08-28 |
Family
ID=35064703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DKPA200601181A DK179025B1 (da) | 2005-09-16 | 2006-09-14 | Fiskevaccine |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7794724B2 (da) |
| EP (1) | EP1928898B1 (da) |
| JP (1) | JP5300479B2 (da) |
| CA (1) | CA2622610C (da) |
| DK (1) | DK179025B1 (da) |
| NO (1) | NO341881B1 (da) |
| WO (1) | WO2007031572A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK179025B1 (da) * | 2005-09-16 | 2017-08-28 | Intervet Int Bv | Fiskevaccine |
| TW200936759A (en) * | 2007-12-21 | 2009-09-01 | Intervet Int Bv | Fish vaccine |
| NO333242B1 (no) * | 2008-02-08 | 2013-04-15 | Pharmaq As | Sammensetning, medisinsk anvendelse og fremgangsmate som omfatter salmonid alfavirus |
| NO346489B1 (no) * | 2008-02-08 | 2022-09-05 | Pharmaq As | Anvendelse av inaktivert SAV i fremstilling av en vaksine. |
| WO2011041789A1 (en) * | 2009-10-02 | 2011-04-07 | The Trustees Of Columbia University In The City Of New York | Piscine reovirus immunogenic compositions |
| DK179920B1 (da) | 2010-04-21 | 2019-10-07 | Pharmaq As | Nucleic acid sequences of a fish virus and the use thereof |
| WO2012089749A1 (en) * | 2010-12-29 | 2012-07-05 | Intervet International B.V. | Salmonid alphavirus protein e2 |
| EP2688587B2 (en) * | 2011-03-25 | 2023-08-16 | Intervet International B.V. | Salmonid alphavirus vaccine |
| GB201204280D0 (en) * | 2012-03-09 | 2012-04-25 | Univ Nordland | Methods |
| WO2014041189A1 (en) * | 2012-09-17 | 2014-03-20 | Novartis Ag | Salmonid alphavirus and uses thereof |
| EP2950816B1 (en) | 2013-02-04 | 2019-07-31 | Schweitzer Biotech Company Ltd. | The use of dna sequences encoding an interferon as vaccine adjuvants |
| GB2551984B (en) | 2016-06-30 | 2019-01-16 | Pharmaq As | Fish virus |
| NO20200827A1 (en) * | 2017-12-26 | 2020-07-14 | Univ Chile | Vaccine formulation for fish based on lipid nanovesicles,particularly a proteoliposome or cochleate, with activity against the salmonid rickettsial syndrome (srs) |
| CA3123504A1 (en) * | 2018-12-21 | 2020-06-25 | Intervet International B.V. | Serum free intracellular pathogen vaccine |
| WO2021123099A1 (en) * | 2019-12-20 | 2021-06-24 | Intervet International B.V. | Reassorted isa virus |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2068989T3 (es) | 1989-02-04 | 1995-05-01 | Akzo Nobel Nv | Tocoles como adyuvante en vacunas. |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| ATE251667T1 (de) | 1994-10-18 | 2003-10-15 | Akzo Nobel Nv | Virus, welches die pankreas-krankheit bei fischen verursacht |
| ATE369429T1 (de) | 1998-05-08 | 2007-08-15 | Intervet Int Bv | Strukturproteine des virus, welches die pankreas- krankheit bei fischen verursacht, und ihre verwendungen |
| EP1140152B1 (en) | 1998-12-21 | 2003-08-06 | Akzo Nobel N.V. | Method to produce inactivated w/o emulsion adjuvated vaccines |
| FR2839453B1 (fr) | 2002-05-07 | 2007-05-11 | Agronomique Inst Nat Rech | Utilisation de novirhabdovirus modifies pour l'obtention de vaccins |
| DK179025B1 (da) * | 2005-09-16 | 2017-08-28 | Intervet Int Bv | Fiskevaccine |
-
2006
- 2006-09-14 DK DKPA200601181A patent/DK179025B1/da active
- 2006-09-15 CA CA2622610A patent/CA2622610C/en active Active
- 2006-09-15 US US12/066,868 patent/US7794724B2/en active Active
- 2006-09-15 EP EP06793552.8A patent/EP1928898B1/en active Active
- 2006-09-15 WO PCT/EP2006/066401 patent/WO2007031572A1/en not_active Ceased
- 2006-09-15 JP JP2008530541A patent/JP5300479B2/ja active Active
-
2008
- 2008-02-28 NO NO20081043A patent/NO341881B1/no unknown
-
2010
- 2010-08-16 US US12/857,015 patent/US8435536B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1928898A1 (en) | 2008-06-11 |
| NO341881B1 (no) | 2018-02-12 |
| US20090162388A1 (en) | 2009-06-25 |
| WO2007031572A1 (en) | 2007-03-22 |
| DK179025B1 (da) | 2017-08-28 |
| CA2622610A1 (en) | 2007-03-22 |
| US8435536B2 (en) | 2013-05-07 |
| JP2009507509A (ja) | 2009-02-26 |
| US7794724B2 (en) | 2010-09-14 |
| US20110135659A1 (en) | 2011-06-09 |
| NO20081043L (no) | 2008-04-07 |
| CA2622610C (en) | 2017-02-21 |
| JP5300479B2 (ja) | 2013-09-25 |
| EP1928898B1 (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK200601181A (da) | Fiskevaccine | |
| JP2023082054A5 (da) | ||
| WO2007002261A3 (en) | IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF | |
| JP2009268467A5 (da) | ||
| JP2006526414A5 (da) | ||
| UA98620C2 (uk) | Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2 | |
| JP2005120106A5 (da) | ||
| EP3552622A3 (en) | Priming of an immune response | |
| JP2008508859A5 (da) | ||
| NZ591415A (en) | Haemophilus influenzae type B | |
| RU2009123028A (ru) | F-белок респираторно-синцитиального вируса (rsv) и его применение | |
| NO20063026L (no) | Antistoffer | |
| RU2017127024A (ru) | Герпесвирус с измененным спектром мишеней, содержащий гибридный гликопротеин н | |
| JP2012516140A5 (da) | ||
| JP2014504297A5 (da) | ||
| EP2289544A3 (en) | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto | |
| JP2012506699A5 (da) | ||
| EP2293079A3 (en) | Use of precursors of enkephalins and/or their fragments in medical diagnostics | |
| MXPA06008217A (es) | Vacunas con subunidad de lawsonia intracellularis. | |
| WO2003095480A3 (en) | Brachyspira hyodysenteriae vaccine | |
| WO2005026200A3 (en) | Lawsonia intracellularis subunit vaccine | |
| JP2008539164A5 (da) | ||
| WO2007064844A3 (en) | Anti-viral griffithsin compounds, compositions, and methods of use | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
| WO2004007726A3 (en) | Brachyspira hyodysenteriae vaccine |